Literature DB >> 30803978

GPs' management of polypharmacy and therapeutic dilemma in patients with multimorbidity: a cross-sectional survey of GPs in France.

Hélène Carrier1, Anna Zaytseva2, Aurélie Bocquier3, Patrick Villani4, Hélène Verdoux5, Martin Fortin6, Pierre Verger3.   

Abstract

BACKGROUND: GPs are confronted with therapeutic dilemmas in treating patients with multimorbidity and/or polypharmacy when unfavourable medication risk-benefit ratios (RBRs) conflict with patients' demands. AIM: To understand GPs' attitudes about prescribing and/or deprescribing medicines for patients with multimorbidity and/or polypharmacy, and factors associated with their decisions. DESIGN AND
SETTING: Cross-sectional survey in 2016 among a national panel of 1266 randomly selected GPs in private practice in France.
METHOD: GPs' opinions and attitudes were explored using a standardised questionnaire including a case vignette about a female treated for multiple somatic diseases, sleeping disorders, and chronic pain. Participants were randomly assigned one of eight versions of this case vignette, varying by patient age, socioprofessional status, and stroke history. Backward selection was used to identify factors associated with GPs' decisions about drugs they considered inappropriate.
RESULTS: Nearly all (91.4%) responders felt comfortable or fairly comfortable deprescribing inappropriate medications, but only 34.7% decided to do so often or very often. In the clinical vignette, most GPs chose to discontinue symptomatic medications (for example, benzodiazepine, paracetamol/tramadol) because of unfavourable RBRs. When patients asked for ketoprofen for persistent sciatica, 94.1% considered this prescription risky, but 25.6% would prescribe it. They were less likely to prescribe it to older patients (adjusted odds ratio [AOR] 0.48, 95% confidence interval [CI] = 0.36 to 0.63), or those with a stroke history (AOR 0.55, 95% CI = 0.42 to 0.72).
CONCLUSION: In therapeutic dilemmas, some GPs choose to prioritise patients' requests over iatrogenic risks. GPs need pragmatic implementation tools for handling therapeutic dilemmas, and to improve their skills in medication management and patient engagement in such situations. © British Journal of General Practice 2019.

Entities:  

Keywords:  cross-sectional survey; general practice; multimorbidity; polypharmacy; risk–benefit ratio

Mesh:

Year:  2019        PMID: 30803978      PMCID: PMC6428490          DOI: 10.3399/bjgp19X701801

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  27 in total

Review 1.  Clinical vignette-based surveys: a tool for assessing physician practice variation.

Authors:  Jon Veloski; Stephen Tai; Adam S Evans; David B Nash
Journal:  Am J Med Qual       Date:  2005 May-Jun       Impact factor: 1.852

Review 2.  Shared decision making: examining key elements and barriers to adoption into routine clinical practice.

Authors:  France Légaré; Holly O Witteman
Journal:  Health Aff (Millwood)       Date:  2013-02       Impact factor: 6.301

3.  Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?

Authors:  Amaia Calderón-Larrañaga; Beatriz Poblador-Plou; Francisca González-Rubio; Luis Andrés Gimeno-Feliu; José María Abad-Díez; Alexandra Prados-Torres
Journal:  Br J Gen Pract       Date:  2012-12       Impact factor: 5.386

Review 4.  Patient barriers to and enablers of deprescribing: a systematic review.

Authors:  Emily Reeve; Josephine To; Ivanka Hendrix; Sepehr Shakib; Michael S Roberts; Michael D Wiese
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

5.  Measuring the quality of physician practice by using clinical vignettes: a prospective validation study.

Authors:  John W Peabody; Jeff Luck; Peter Glassman; Sharad Jain; Joyce Hansen; Maureen Spell; Martin Lee
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

6.  General practitioners' choices and their determinants when starting treatment for major depression: a cross sectional, randomized case-vignette survey.

Authors:  Hélène Dumesnil; Sébastien Cortaredona; Hélène Verdoux; Rémy Sebbah; Alain Paraponaris; Pierre Verger
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

7.  Current guidelines have limited applicability to patients with comorbid conditions: a systematic analysis of evidence-based guidelines.

Authors:  Marjolein Lugtenberg; Jako S Burgers; Carolyn Clancy; Gert P Westert; Eric C Schneider
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

Review 8.  Inappropriate medication use among the elderly: a systematic review of administrative databases.

Authors:  Lusiele Guaraldo; Fabíola G Cano; Glauciene S Damasceno; Suely Rozenfeld
Journal:  BMC Geriatr       Date:  2011-11-30       Impact factor: 3.921

9.  Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study.

Authors:  Jan Schuling; Henkjan Gebben; Leonardus Johannes Gerardus Veehof; Flora Marcia Haaijer-Ruskamp
Journal:  BMC Fam Pract       Date:  2012-07-09       Impact factor: 2.497

10.  GPs' perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research.

Authors:  Carol Sinnott; Sheena Mc Hugh; John Browne; Colin Bradley
Journal:  BMJ Open       Date:  2013-09-13       Impact factor: 2.692

View more
  2 in total

1.  GPs' mindlines on deprescribing antihypertensives in older patients with multimorbidity: a qualitative study in English general practice.

Authors:  Karolina Kuberska; Fiona Scheibl; Carol Sinnott; James P Sheppard; Mark Lown; Marney Williams; Rupert A Payne; Jonathan Mant; Richard J McManus; Jenni Burt
Journal:  Br J Gen Pract       Date:  2021-06-24       Impact factor: 6.302

2.  Association between recorded medication reviews in primary care and adequate drug treatment management - a cross-sectional study.

Authors:  Naldy Parodi López; Staffan A Svensson; Susanna M Wallerstedt
Journal:  Scand J Prim Health Care       Date:  2021-09-22       Impact factor: 2.581

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.